ClinPGx Blog (Page 33)

Sign in Subscribe

More issues

GWAS on SSRI treatment outcome in patients with depression: ISPC cohort and meta-analysis

The treatment response to selective serotonin reuptake inhibitors (SSRIs), a major class of antidepressant drugs, varies considerably between patients. The International SSRI PharmacogenomicsConsortium (ISPC) was established with the primary goal of identifying genetic variations that may contribute to SSRI treatment outcome in patients with depressive disorder. The ISPC includes eight

PharmGKB and Stanford Law School student collaboration

The Stanford Law School blog recently highlighted the collaboration between Stanford law students and PharmGKB to write a response to the FDA proposed regulation of laboratory developed tests. Read more about the Juelsgaard Intellectual Property and Innovation Clinic students and their work.

NAT2 plays a role in insulin sensitivity

N-acetyltransferase 2 (NAT2) has long been known to metabolize xenobiotics but the endogenous substrates of NAT2 remain unknown. A new study published in “The Journal of Clinical Investigation” provides convincing evidence that NAT2 plays a role in the regulation of insulin sensitivity. The authors of the study reported that

New CPIC Guideline: CYP3A5 and Tacrolimus

Guidelines regarding the use of pharmacogenetic tests for CYP3A5 in dosing tacrolimus have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Tacrolimus is an immunosuppressive agent administered to transplant recipients to prevent and treat allograft rejection. Clinical use of tacrolimus is complicated by its

ABCB5 and haloperidol-induced toxicity: Results from a new study

Approximately 50% of patients treated with the antipsychotic drug haloperidol will develop extrapyramidal symptoms, a category that includes tremors, parkinsonism and decreased spontaneous movement. However, studies looking into the genetic variations associated with the development of these symptoms have been limited. In a study recently published in PLOS Medicine, Zheng

Our 10-step guide to enabling your PGx study to be curated

At PharmGKB we manually curate pharmacogenetic (PGx) associations found in published articles and add them to our database. However, lack of information or clarity is unfortunately common in publications and these hurdles make it difficult or impossible to curate a particular association. We have published a guideline in Clinical Pharmacology

PharmGKB VIP summary for CFTR published

The PharmGKB summary describing CFTR as a pharmacogene has been published by Pharmacogenetics & Genomics. Genetic variants within the CFTR gene are the target of new Cystic Fibrosis therapies and drugs in development. The hope is that patients will be better treated with personalized medicines tailored to the underlying defects

FDA Proposed Regulation of Laboratory Developed Tests (LDTs)

Dear Colleagues, As you may know, the FDA is considering regulating laboratory developed tests (LDTs) and had an open comment period that ended February 2, 2015. We would like to share with you a response that we wrote from our perspective at PharmGKB, working with the Stanford Law School “IP

Genomic CDS Sandbox

<!-- /* Font Definitions */ @font-face {font-family:"ＭＳ明朝"; mso-font-charset:78; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"ＭＳ明朝"; mso-font-charset:78; mso-generic-font-family:auto;

Pathways of acetaminophen metabolism at therapeutic versus toxic doses

We have updated the acetaminophen pharmacokinetic pathway, which depicts the metabolism at therapeutic doses. In addition we added a new pathway illustrating the metabolism of acetaminophen at toxic doses.Acetaminophen (paracetamol) is widely used for its analgesic and antipyretic properties. Acetaminophen is mostly converted by glucuronidation and sulfation. A minor